BeyondSpring Inc logo

BYSIBeyondSpring Inc

NASDAQ · Healthcare · Biotechnology

$0.60

+$0.00 (+0.02%)

BeyondSpring Inc (BYSI) is a biotechnology company listed on NASDAQ. It is led by Lan Huang Ph.D., based in 100 Campus Drive, Florham Park, NJ, United States, 07932, with about 40 employees. BeyondSpring Inc., a clinical stage biopharmaceutical company, focuses on the development of cancer therapies. It operates through two segments: Plinabulin pipeline and TPD platform. The company's lead asset is the Plinabulin, a selective immunomodulating microtubule-binding agent that has completed Phase III clinical trials for treatment of non-small cell lung cancer (NSCLC); and as an anti-cancer agent, as well as for the prevention of chemotherapy-induced neutropenia. It is also developing Plinabulin in combination with docetaxel vs. docetaxel alone for the treatment of NSCLC and epidermal growth factor receptor wild type. In addition, the company develops Plinabulin in combination with various immuno-oncology agents and chemotherapy and radiation; nivolumab, a PD-1 antibody that is has completed phase 1 clinical trials for the treatment of non-small cell lung cancer; ipilimumab, a CTLA-4 antibody for the treatment of extensive-stage small cell lung cancer; in combination with PD-1 or PD-L1 antibodies and radiation for the treatment of various cancers; and pembrolizumab, etoposide, and platinum to treat extensive-stage small cell lung cancer. Further, it engages in the development of three small molecule immune agents in preclinical stages; and a drug discovery platform to develop therapeutic agents from internal research and development efforts and from collaboration. The company was founded in 2010 and is headquartered in Florham Park, New Jersey.

Net income was -$849.0K. BYSI currently screens at market cap $92.3M.

Use this BYSI page for company research — sector, financials, and the latest filing takeaway — not a live tape. The session quote (last, range, volume) lives on the BYSI quote page. Cached 10-K, 10-Q, 8-K, and Form 4 exhibits are on the BYSI SEC filings page. Lician reads the product cache first so this HTML stays unique to BeyondSpring Inc even when a live quote feed is slow.

About BeyondSpring Inc

BeyondSpring Inc., a clinical stage biopharmaceutical company, focuses on the development of cancer therapies. It operates through two segments: Plinabulin pipeline and TPD platform. The company's lead asset is the Plinabulin, a selective immunomodulating microtubule-binding agent that has completed Phase III clinical trials for treatment of non-small cell lung cancer (NSCLC); and as an anti-cancer agent, as well as for the prevention of chemotherapy-induced neutropenia. It is also developing Plinabulin in combination with docetaxel vs. docetaxel alone for the treatment of NSCLC and epidermal growth factor receptor wild type. In addition, the company develops Plinabulin in combination with various immuno-oncology agents and chemotherapy and radiation; nivolumab, a PD-1 antibody that is has completed phase 1 clinical trials for the treatment of non-small cell lung cancer; ipilimumab, a CTLA-4 antibody for the treatment of extensive-stage small cell lung cancer; in combination with PD-1 or PD-L1 antibodies and radiation for the treatment of various cancers; and pembrolizumab, etoposide, and platinum to treat extensive-stage small cell lung cancer. Further, it engages in the development of three small molecule immune agents in preclinical stages; and a drug discovery platform to develop therapeutic agents from internal research and development efforts and from collaboration. The company was founded in 2010 and is headquartered in Florham Park, New Jersey.

BYSI Key Statistics

Market Cap

$92.32M

Volume

44,391

Previous Close

$0.71

Day Range

$0.71$0.77

00

EPS

$0.00

Revenue

$0.00

Net Income

-$1.01M

Gross Profit

$0.00

Free Cash Flow

-$19.72M

Debt to Equity

0.00

Employees

40

BYSI Financials

Annual income statement in USD. Latest reported periods first.

BYSI annual income statement across FY2025, FY2024
LineFY2025FY2024
Revenue$0.00$0.00
Cost of Revenue$0.00$0.00
Gross Profit$0.00$0.00
Operating Income-$8.95M-$8.75M
Net Income-$1.01M-$11.12M
EPS (Diluted)$0.00$0.00

Total Assets

$25.93M

Total Debt

$0.00

Shareholders' Equity

-$32.16M

Cash & Equivalents

$7.79M

Operating Cash Flow

-$19.77M

Free Cash Flow

-$19.72M

BeyondSpring Inc Company Information

Co-Founder, Chairman & CEO
Lan Huang Ph.D.
Headquarters
100 Campus Drive, Florham Park, NJ, United States, 07932
Phone
646-305-6387
IPO / Founded
2017-03-09
Industry
Biotechnology
Data Updated:

Upcoming Events for BYSI